Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan Maertens(Universitair Ziekenhuis Leuven), Issam Raad(The University of Texas MD Anderson Cancer Center), Kieren A. Marr(Johns Hopkins University), Thomas F. Patterson(The University of Texas Health Science Center), Dimitrios P. Kontoyiannis(The University of Texas MD Anderson Cancer Center), Oliver A. Cornely(University of Cologne), Eric J. Bow(University of Manitoba), Galia Rahav(Tel Aviv University), Dionysios Neofytos(Johns Hopkins University), Mickaël Aoun(Institut Jules Bordet), John W. Baddley(Birmingham VA Medical Center), Michael Giladi(Tel Aviv University), Werner Heinz(University of Würzburg), Raoul Herbrecht(Université de Strasbourg), William Hope(University of Liverpool), Meinolf Karthaus(München Klinik Neuperlach), Dong‐Gun Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Olivier Lortholary(Université Paris Cité), Vicki A. Morrison(University of Minnesota Medical Center), Ilana Oren(Technion – Israel Institute of Technology), Dominik Selleslag(AZ Sint-Jan), Shmuel Shoham(Johns Hopkins University), George R. Thompson(University of California Davis Medical Center), Misun Lee(Astellas Pharma (United States)), Rochelle Maher(Astellas Pharma (United States)), Anne‐Hortense Schmitt‐Hoffmann(Basilea Pharmaceutica (Switzerland)), Bernhardt Zeiher(Astellas Pharma (United States)), Andrew J. Ullmann(University of Würzburg)
Cited by 964
Abstract
Related Papers
No related papers found
Powered by citation graph analysis